Cyprotex awarded 2013 Biomedical Service Company of the Year
4th December 2013
Cyprotex PLC, the specialist ADME-Tox contract research organisation, has been awarded ‘Biomedical Service Provider of the Year’ at the prestigious Bionow Annual Awards Dinner on the 28th November 2013. The event was attended by over 300 executives from across the biomedical industry and it showcased the very best of this world class biomedical sector. The judging panel included representatives from AstraZeneca, Baker Tilly, Novartis Vaccines, TRUSTECH, UL EduNeering, Waters Corporation, DWF LLP, Pinsent Masons LLP and MIMIT.
The decision was based on Cyprotex’s strong application which highlighted the strong growth in the company (in 2012, revenues up 22.3% in 2012, robust EDITDA of £0.7 million, an operating profit of £0.32 million and 78 new customers) as well as significant ongoing contracts with Pfizer and the US EPA, and development of several cutting edge technologies such as eCiphrCardio and eCiphrNeuro in 2013.
Anthony Baxter PhD, chief executive of Cyprotex, comments: “We are delighted to have won the prestigious Bionow Biomedical Service Company of the Year award. Our dedicated team at our facilities in the UK and the US has made this possible and they have worked hard to achieve where we are today. Investment of £7 million in the company by Harwood Capital as announced in August this year has facilitated expansion into a laboratory at the Alderley Park’s Biohub site as well as a high throughput laboratory over at our Watertown site - to be launched in the New Year. We are looking forward to further growth and expansion during 2014.”
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.